Influenza drug resistance

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 4, 2011, Pages 409-422

  Pizzorno, Andrés ^a   Abed, Yacine ^a   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

adamantanes; antivirals; Influenza; neuraminidase inhibitors; oseltamivir; peramivir; resistance; zanamivir

Indexed keywords

A 315675; ADAMANTANE DERIVATIVE; AMANTADINE; ANTIVIRUS AGENT; BETAMETHASONE; CELECOXIB; DAS 181; FAVIPIRAVIR; FLUDASE; GAMMA INTERFERON; GEMFIBROZIL; ION CHANNEL; LANINAMIVIR; LANINAMIVIR OCTANOATE; MATRIX PROTEIN; MESALAZINE; METHYLPREDNISOLONE; N ACETYLNEURAMINIC ACID; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; RIBONUCLEOPROTEIN; RIMANTADINE; RNA POLYMERASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; ZANAMIVIR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANXIETY; CRYSTAL STRUCTURE; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; GENOTYPE; HUMAN; IC 50; IN VITRO STUDY; INFLUENZA; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INSOMNIA; MONOTHERAPY; MORTALITY; NAUSEA; NONHUMAN; PANDEMIC INFLUENZA; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SURVIVAL; SYRUP; TABLET; VACCINATION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; VOMITING;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN;

EID: 80051964411     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1283281     Document Type: Review

References (160)

1. Hayden F, Palese P. Influenza virus. In: Richman D D. Whiley R J. Hayden F G. eds. Clinical Virology. 2nd ed. Washington, DC ASM Press 2002 891-920
2. Claas E C., de Jong J C., van Beek R, Rimmelzwaan G F., Osterhaus A D. Human influenza virus A/HongKong/156/97 (H5N1) infection. Vaccine 1998 16 910 977-978 (Pubitemid 28276010)
3. Claas E C., Osterhaus A D., van Beek R, al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998 351 9101 472-477 (Pubitemid 28070093)
4. Yuen K Y., Chan P K., Peiris M et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998 351 9101 467-471 (Pubitemid 28070092)
5. Koopmans M, Wilbrink B, Conyn M et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004 363 9409 587-593 (Pubitemid 38264175)
6. Peiris M, Yuen K Y., Leung C W. et al. Human infection with influenza H9N2. Lancet 1999 354 9182 916-917 (Pubitemid 29424025)
7. Uyeki T M., Chong Y H., Katz J M. et al. Lack of evidence for human-to-human transmission of avian influenza A (H9N2) viruses in Hong Kong, China 1999. Emerg Infect Dis 2002 8 2 154-159 (Pubitemid 34202437)
8. Neuzil K M., Zhu Y, Griffin M R. et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002 185 2 147-152 (Pubitemid 34056437)
9. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenzaUnited States, 19762007. MMWR Morb Mortal Wkly Rep 2010 59 33 1057-1062
10. World Healh Organization (WHO). Influenza fact sheet No. 211. April 2009. http://www.who.int/mediacentre/factsheets/fs211/en/index.html Accessed February 2011
11. Harper S A., Bradley J S., Englund J A. et al, Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and childrendiagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009 48 8 1003-1032
12. Monto A S., Ohmit S E., Hornbuckle K, Pearce C L. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 1995 39 10 2224-2228
13. Martin K, Helenius A. Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import. Cell 1991 67 1 117-130 (Pubitemid 121001429)
14. Hay A J., Wolstenholme A J., Skehel J J., Smith M H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985 4 11 3021-3024
15. Pielak R M., Chou J J. Flu channel drug resistance: a tale of two sites. Protein Cell 2010 1 3 246-258
16. Couch R B. Prevention and treatment of influenza. N Engl J Med 2000 343 24 1778-1787
17. Kawai N, Ikematsu H, Iwaki N et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 2005 40 9 1309-1316 (Pubitemid 40570241)
18. Keyser L A., Karl M, Nafziger A N., Bertino J S. Jr. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 2000 160 10 1485-1488 (Pubitemid 30327452)
19. Lynch J P. III, Walsh E E. Influenza: evolving strategies in treatment and prevention. Semin Respir Crit Care Med 2007 28 2 144-158 (Pubitemid 46676909)
20. Klimov A I., Rocha E, Hayden F G., Shult P A., Roumillat L F., Cox N J. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995 172 5 1352-1355
21. Masuda H, Suzuki H, Oshitani H et al. Incidence of amantadine-resistant influenza A viruses in sentinel surveillance sites and nursing homes in Niigata, Japan. Microbiol Immunol 2000 44 10 833-839
22. Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis 2002 34 5 E23-E25
23. Saito R, Sakai T, Sato I et al. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. J Clin Microbiol 2003 41 5 2164-2165 (Pubitemid 36576555)
24. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003 188 1 57-61 (Pubitemid 36829742)
25. Centers for Disease Control and Prevention (CDC). Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009 58 16 433-435
26. Ziegler T, Hemphill M L., Ziegler M L. et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis 1999 180 4 935-939 (Pubitemid 30070171)
27. Bright R A., Medina M J., Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005 366 9492 1175-1181 (Pubitemid 41393595)
28. Deyde V M., Xu X, Bright R A. et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007 196 2 249-257 (Pubitemid 47047464)
29. Cheung C L., Rayner J M., Smith G J. et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 2006 193 12 1626-1629 (Pubitemid 43839465)
30. Sweet C, Hayden F G., Jakeman K J., Grambas S, Hay A J. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis 1991 164 5 969-972
31. Abed Y, Goyette N, Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother 2005 49 2 556-559 (Pubitemid 40175661)
32. Hayden F G., Belshe R B., Clover R D., Hay A J., Oakes M G., Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989 321 25 1696-1702 (Pubitemid 20020544)
33. World Health Organization (WHO). WHO guidelines for pharmacological management of pandemic influenza A (H1N1) 2009 and other influenza viruses. February 2010. http://www.who.int/csr/resources/publications/swineflu/h1n1- guidelines-pharmaceutical-mngt.pdf Accessed March 2011
34. Griffin J A., Basak S, Compans R W. Effects of hexose starvation and the role of sialic acid in influenza virus release. Virology 1983 125 2 324-334 (Pubitemid 13120110)
35. Liu C, Eichelberger M C., Compans R W., Air G M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 1995 69 2 1099-1106
36. Matrosovich M N., Matrosovich T Y., Gray T, Roberts N A., Klenk H D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004 78 22 12665-12667 (Pubitemid 39458784)
37. Colman P M., Varghese J N., Laver W G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983 303 5912 41-44 (Pubitemid 13125071)
38. Baker A T., Varghese J N., Laver W G., Air G M., Colman P M. Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins 1987 2 2 111-117
39. Burmeister W P., Ruigrok R W., Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J 1992 11 1 49-56
40. Mendel D B., Roberts N A. In-vitro and in-vivo efficacy of influenza neuraminidase inhibitors. Curr Opin Infect Dis 1998 11 6 727-732 (Pubitemid 29020883)
41. Sidwell R W., Smee D F. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin Investig Drugs 2002 11 6 859-869 (Pubitemid 34618818)
42. Ferraris O, Kessler N, Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res 2005 68 1 43-48 (Pubitemid 41338581)
43. Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res 2002 54 3 143-147 (Pubitemid 34327680)
44. Naughtin M, Dyason J C., Mardy S, Sorn S, von Itzstein M, Buchy P. Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus. Antimicrob Agents Chemother 2011 55 5 2004-2010
45. Sheu T G., Deyde V M., Okomo-Adhiambo M et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008 52 9 3284-3292
46. U.S. Food and Drug Administration (FDA). Relenza prescribing information. January 2008. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm183783.htm Accessed April 2011
47. U.S. Food and Drug Administration (FDA). Tamiflu prescribing information. January 2008. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm095044.htm Accessed April 2011
48. Barroso L, Treanor J, Gubareva L, Hayden F G. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005 10 8 901-910 (Pubitemid 43076341)
49. Birnkrant D, Cox E. The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009 361 23 2204-2207
50. BioCryst Pharmaceuticals, Inc. BioCryst's partner Shionogi receives marketing and manufacturing approval for peramivir in Japan. January 13, 2010. http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=437335 Accessed February 2011
51. Abed Y, Bourgault A M., Fenton R J. et al. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J Infect Dis 2002 186 8 1074-1080 (Pubitemid 35177108)
52. McKimm-Breschkin J L. Resistance of influenza viruses to neuraminidase inhibitorsa review. Antiviral Res 2000 47 1 1-17 (Pubitemid 30621392)
53. Russell R J., Haire L F., Stevens D J. et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006 443 7107 45-49 (Pubitemid 44344043)
54. Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004 364 9436 759-765 (Pubitemid 39165094)
55. Ives J A., Carr J A., Mendel D B. et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002 55 2 307-317 (Pubitemid 34718130)
56. Tai C Y., Escarpe P A., Sidwell R W. et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998 42 12 3234-3241 (Pubitemid 28553746)
57. Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res 2007 74 2 159-162 (Pubitemid 46436166)
58. Taylor N R., von Itzstein M. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J Med Chem 1994 37 5 616-624 (Pubitemid 24102181)
59. Moscona A. Oseltamivir resistancedisabling our influenza defenses. N Engl J Med 2005 353 25 2633-2636 (Pubitemid 41817709)
60. Barnett J M., Cadman A, Burrell F M. et al. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 1999 265 2 286-295 (Pubitemid 30022223)
61. Baum E Z., Wagaman P C., Ly L et al. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antiviral Res 2003 59 1 13-22 (Pubitemid 36773886)
62. Weinstock D M., Gubareva L V., Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003 348 9 867-868 (Pubitemid 36245772)
63. Le Q M., Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005 437 7062 1108 (Pubitemid 41509341)
64. de Jong M D., Tran T T., Truong H K. et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005 353 25 2667-2672 (Pubitemid 41817715)
65. World Health Organization (WHO). Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010. Wkly Epidemiol Rec 2009 85 6 37-40
66. Ison M G., Gubareva L V., Atmar R L., Treanor J, Hayden F G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006 193 6 760-764
67. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006 43 12 1555-1561 (Pubitemid 44901897)
68. Whitley R J., Hayden F G., Reisinger K S. et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001 20 2 127-133 (Pubitemid 32151932)
69. Carr S, Ilyushina N A., Franks J et al. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J 2011 30 4 284-288
70. Hurt A C., Holien J K., Parker M, Kelso A, Barr I G. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009 83 20 10366-10373
71. Dapat C, Suzuki Y, Saito R et al. Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. Emerg Infect Dis 2010 16 3 493-496
72. Gubareva L V. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004 103 12 199-203 (Pubitemid 38649080)
73. Gubareva L V., Matrosovich M N., Brenner M K., Bethell R C., Webster R G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998 178 5 1257-1262
74. Oakley A J., Barrett S, Peat T S. et al. Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J Med Chem 2010 53 17 6421-6431
75. Abed Y, Goyette N, Boivin G. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir Ther 2004 9 4 577-581 (Pubitemid 39150215)
76. Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 2006 11 8 971-976 (Pubitemid 44955172)
77. Pizzorno A, Bouhy X, Abed Y, Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011 203 1 25-31
78. Yen H L., Hoffmann E, Taylor G et al. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol 2006 80 17 8787-8795 (Pubitemid 44384887)
79. Jackson D, Barclay W, Zürcher T. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 2005 55 2 162-169 (Pubitemid 40331140)
80. McKimm-Breschkin J, Trivedi T, Hampson A et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003 47 7 2264-2272 (Pubitemid 36753582)
81. Roberts N A. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos Trans R Soc Lond B Biol Sci 2001 356 1416 1895-1897 (Pubitemid 34099095)
82. Mungall B A., Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 20002002 influenza seasons. Virus Res 2004 103 1-2 195-197 (Pubitemid 38649079)
83. Monto A S., McKimm-Breschkin J L., Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006 50 7 2395-2402 (Pubitemid 43993177)
84. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005 55 Suppl 1 i5-i21 (Pubitemid 40331165)
85. Hauge S H., Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 200708. Emerg Infect Dis 2009 15 2 155-162
86. Meijer A, Lackenby A, Hungnes O et al, European Influenza Surveillance Scheme. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009 15 4 552-560
87. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill 2009 14 (5). pii 19112
88. Dharan N J., Gubareva L V., Meyer J J. et al, Oseltamivir-Resistance Working Group. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009 301 10 1034-1041
89. Centers for Disease Control and Prevention (CDC). Update: influenza activityUnited States, September 28, 2008April 4, 2009, and composition of the 2009-10 influenza vaccine. MMWR Morb Mortal Wkly Rep 2009 58 14 369-374
90. Nguyen H T., Sheu T G., Mishin V P., Klimov A I., Gubareva L V. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother 2010 54 9 3671-3677
91. World Health Organization (WHO). Weekly update on oseltamivir resistance in influenza A(H1N1) 2009 viruses. April 6, 2011. http://www.who.int/csr/ disease/influenza/2011-04-08-weekly-web-update-oseltamivir-resistance.pdf Accessed April 2011
92. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxisNorth Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009 58 35 969-972
93. Nguyen H T., Fry A M., Loveless P A., Klimov A I., Gubareva L V. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 2010 51 8 983-984
94. Lackenby A, Moran Gilad J, Pebody R et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill 2011 16 5 16
95. Herlocher M L., Truscon R, Elias S et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004 190 9 1627-1630 (Pubitemid 39411012)
96. Baz M, Abed Y, Simon P, Hamelin M E., Boivin G. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis 2010 201 5 740-745
97. Rameix-Welti M A., Enouf V, Cuvelier F, Jeannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog 2008 4 7 e1000103
98. Ciancio B C., Meerhoff T J., Kramarz P et al. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. Euro Surveill 2009 14 46 14
99. Bloom J D., Gong L I., Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010 328 5983 1272-1275
100. Hamelin M E., Baz M, Abed Y et al. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog 2010 6 7 e1001015
101. Hamelin M E., Baz M, Bouhy X et al. Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets. Antivir Ther 2011 In press
102. Gristina G, Nardi G, Orazi D et al. Prone positioning and intravenous zanamivir may represent effective alternatives for patients with severe ARDS virus A (H1N1) related pneumonia in hospitals with no access to ECMO. Crit Care Res Pract 2010 2010 146456
103. Härter G, Zimmermann O, Maier L et al. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis 2010 50 9 1249-1251
104. Dohna-Schwake C, Schweiger B, Felderhoff-Müser U et al. Severe H1N1 infection in a pediatric liver transplant recipient treated with intravenous zanamivir: efficiency and complications. Transplantation 2010 90 2 223-224
105. Busani S, Girardis M, Biagioni E, Pasetto A, Sambri V. Surfactant therapy and intravenous zanamivir in severe respiratory failure due to persistent influenza A/H1N1 2009 virus infection. Am J Respir Crit Care Med 2010 182 10 1334
106. Brown A N., McSharry J J., Weng Q, Adams J R., Kulawy R, Drusano G L. Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 2011 55 4 1740-1746
107. GlaxoSmithKline. GlaxoSmithKline commences Phase III study of intravenous zanamivir for hospitalised patients with influenza. January 19, 2011. http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-10015.htm Accessed April 2011
108. ClinicalTrials.gov. A study of intravenous zanamivir versus oral oseltamivir in adults and adolescents hospitalized with influenza. October 28, 2010. http://clinicaltrials.gov/ct2/show/NCT01231620?term=zanamivir+IV&rank= 2 Accessed April 2011
109. Kubo S, Tomozawa T, Kakuta M, Tokumitsu A, Yamashita M. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob Agents Chemother 2010 54 3 1256-1264
110. Koyama K, Takahashi M, Oitate M et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother 2009 53 11 4845-4851
111. Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009 53 1 186-192
112. Kubo S, Kakuta M, Yamashita M. In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses [in Japanese]. Jpn J Antibiot 2010 63 5 337-346
113. Watanabe A, Chang S C., Kim M J., Chu D W., Ohashi Y, MARVEL Study Group. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010 51 10 1167-1175
114. Ishizuka H, Yoshiba S, Okabe H, Yoshihara K. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol 2010 50 11 1319-1329
115. Ishizuka H, Yoshiba S, Yoshihara K, Okabe H. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958. J Clin Pharmacol 2011 51 2 243-251
116. Biota Holdings Ltd. LANI Phase III clinical trials in Asia prove successful. August 10, 2009. http://www.biota.com.au/uploaded/154/1021542- 25laniphaseiiiclinicaltri.pdf Accessed February 2011
117. Biota Holdings Ltd. Phase III trial with CS-8958 for flu prevention underway. November 5, 2009. http://www.biota.com.au/uploaded/154/1021585- 54cs8958phaseiiipreventio.pdf Accessed February 2011
118. Biota Holdings Ltd. Inavir approved for sale in Japan. September 13, 2010. http://www.biota.com.au/uploaded/154/1021695-65inavirapprovedforsalein.pdf Accessed February 2011
119. Hanessian S, Bayrakdarian M, Luo X. Total synthesis of A-315675: a potent inhibitor of influenza neuraminidase. J Am Chem Soc 2002 124 17 4716-4721 (Pubitemid 34465010)
120. Baz M, Abed Y, Nehmé B, Boivin G. Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice. Antimicrob Agents Chemother 2009 53 2 791-793
121. Rungrotmongkol T, Udommaneethanakit T, Frecer V, Miertus S. Combinatorial design of avian influenza neuraminidase inhibitors containing pyrrolidine core with a reduced susceptibility to viral drug resistance. Comb Chem High Throughput Screen 2010 13 3 268-277
122. Balfour H H. Jr. Antiviral drugs. N Engl J Med 1999 340 16 1255-1268
123. Brooks M J., Sasadeusz J J., Tannock G A. Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline? Curr Opin Pulm Med 2004 10 3 197-203 (Pubitemid 38520763)
124. Sidwell R W., Bailey K W., Wong M H., Barnard D L., Smee D F. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 2005 68 1 10-17 (Pubitemid 41338577)
125. Kiso M, Takahashi K, Sakai-Tagawa Y et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A 2010 107 2 882-887
126. Furuta Y, Takahashi K, Fukuda Y et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002 46 4 977-981 (Pubitemid 34260339)
127. Furuta Y, Takahashi K, Kuno-Maekawa M et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005 49 3 981-986 (Pubitemid 40327713)
128. Sleeman K, Mishin V P., Deyde V M., Furuta Y, Klimov A I., Gubareva L V. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 2010 54 6 2517-2524
129. Toyama Chemical Co., Ltd. Toyama Chemical Co., Ltd. initiates phase 2 clinical trial in the US of its anti-influenza drug candidate T-705. February 15, 2010. http://www.toyama-chemical.co.jp/eng/news/news100215e.html Accessed March 2011
130. Belser J A., Lu X, Szretter K J. et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007 196 10 1493-1499 (Pubitemid 351411986)
131. Triana-Baltzer G B., Gubareva L V., Nicholls J M. et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 2009 4 11 e7788
132. Hedlund M, Aschenbrenner L M., Jensen K, Larson J L., Fang F. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. J Infect Dis 2010 201 7 1007-1015
133. Triana-Baltzer G B., Sanders R L., Hedlund M et al. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. J Antimicrob Chemother 2011 66 1 15-28
134. U.S. National Institutes of Health (NIH). Randomized, double-blind, placebo controlled phase II study to examine the effects of DAS181 in healthy adult subjects with laboratory confirmed influenza. December 18, 2009. http://clinicaltrials.gov/ct2/show/NCT01037205?term=DAS181&rank=5 Accessed April 2011
135. Ilyushina N A., Hoffmann E, Salomon R, Webster R G., Govorkova E A. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 2007 12 3 363-370 (Pubitemid 46787981)
136. Masihi K N., Schweiger B, Finsterbusch T, Hengel H. Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice. J Chemother 2007 19 3 295-303 (Pubitemid 47075125)
137. Nguyen J T., Hoopes J D., Smee D F. et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009 53 10 4115-4126
138. Nguyen J T., Hoopes J D., Le M H. et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 2010 5 2 e9332
139. Smee D F., Hurst B L., Wong M H. et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 2010 54 1 126-133
140. Duval X, van der Werf S, Blanchon T et al, Bivir Study Group. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010 7 11 e1000362
141. Petersen E, Keld D B., Ellermann-Eriksen S et al. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand J Infect Dis 2011 Feb 10. [Epub ahead of print]
142. Cheung C Y., Poon L L., Lau A S. et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002 360 9348 1831-1837 (Pubitemid 35449422)
143. Peiris J S., Yu W C., Leung C W. et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004 363 9409 617-619 (Pubitemid 38264181)
144. Chan M C., Cheung C Y., Chui W H. et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005 6 135
145. Kobasa D, Jones S M., Shinya K et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007 445 7125 319-323 (Pubitemid 46122819)
146. Ottolini M, Blanco J, Porter D, Peterson L, Curtis S, Prince G. Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model. Pediatr Pulmonol 2003 36 4 290-294 (Pubitemid 37129767)
147. Zheng B J., Chan K W., Lin Y P. et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A 2008 105 23 8091-8096
148. Budd A, Alleva L, Alsharifi M et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007 51 8 2965-2968 (Pubitemid 47206237)
149. Henter J I., Palmkvist-Kaijser K, Holzgraefe B, Bryceson Y T., Palmér K. Cytotoxic therapy for severe swine flu A/H1N1. Lancet 2010 376 9758 2116
150. Quispe-Laime A M., Bracco J D., Barberio P A. et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med 2010 36 1 33-41
151. Confalonieri M, Cifaldi R, Dreas L, Viviani M, Biolo M, Gabrielli M. Methylprednisolone infusion for life-threatening H1N1-virus infection. Ther Adv Respir Dis 2010 4 4 233-237
152. Kidd I M., Down J, Nastouli E et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 2009 374 9694 1036
153. Mishin V P., Hayden F G., Gubareva L V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005 49 11 4515-4520 (Pubitemid 41552580)
154. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin M E., Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009 361 23 2296-2297
155. Hurt A C., Holien J K., Barr I G. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 2009 53 10 4433-4440
156. Carr J, Ives J, Kelly L et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 2002 54 2 79-88 (Pubitemid 34327686)
157. Gubareva L V., Robinson M J., Bethell R C., Webster R G. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997 71 5 3385-3390 (Pubitemid 27172346)
158. Abed Y, Baz M, Boivin G. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus. J Infect Dis 2009 199 2 180-183
159. Memoli M J., Hrabal R J., Hassantoufighi A, Eichelberger M C., Taubenberger J K. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010 50 9 1252-1255
160. Okomo-Adhiambo M, Demmler-Harrison G J., Deyde V M. et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 2010 54 5 1834-1841